NCT00253318View on ClinicalTrials.gov

RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 1, 2005

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Breast Cancer
Interventions
DRUG

Docetaxel

40 mg/m\^2 IV over 1 hour on Day 1.

DRUG

RAD001

30 mg orally on Days 1 and 8.

DRUG

Dexamethasone

8 mg orally twice daily for 3 days, starting 24 hours prior to the administration of Docetaxel.

Trial Locations (1)

77230-1439

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER